Therapy Areas: Vaccines
AstraZeneca's COVID-19 vaccine effective against Delta and Kappa virus variants
23 June 2021 -

British pharmaceutical company AstraZeneca Plc (LON:AZN) has said that its COVID-19 vaccine is effective against Delta and Kappa variants, which were first identified in India, citing a study by Oxford University, Reuters news agency reported on Wednesday.

AstraZeneca stated that this study investigated the ability of monoclonal antibodies in blood from recovered people and from those vaccinated to neutralise the Delta and Kappa variants.

Last week, an analysis by the Public Health England (PHE) had showed that COVID-19 vaccines made by Pfizer Inc (NYSE:PFE) and AstraZeneca offer high protection of over 90% against hospitalisation from the Delta variant.

These latest Oxford study results are built on the recent analysis by PHE, the company said.



Related Headlines